JP2005527510A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005527510A5 JP2005527510A5 JP2003572598A JP2003572598A JP2005527510A5 JP 2005527510 A5 JP2005527510 A5 JP 2005527510A5 JP 2003572598 A JP2003572598 A JP 2003572598A JP 2003572598 A JP2003572598 A JP 2003572598A JP 2005527510 A5 JP2005527510 A5 JP 2005527510A5
- Authority
- JP
- Japan
- Prior art keywords
- type
- phosphodiesterase
- inhibitor
- phosphodiesterase inhibitor
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36296902P | 2002-03-06 | 2002-03-06 | |
| US36262002P | 2002-03-07 | 2002-03-07 | |
| PCT/CA2003/000313 WO2003074082A1 (en) | 2002-03-06 | 2003-03-06 | Formulations and methods of using nitric oxide mimetics in cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005527510A JP2005527510A (ja) | 2005-09-15 |
| JP2005527510A5 true JP2005527510A5 (https=) | 2006-04-20 |
Family
ID=27791719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003572598A Pending JP2005527510A (ja) | 2002-03-06 | 2003-03-06 | 癌の治療において一酸化窒素模倣体を使用するための製剤および方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1492567A1 (https=) |
| JP (1) | JP2005527510A (https=) |
| AU (1) | AU2003208228A1 (https=) |
| CA (1) | CA2478145A1 (https=) |
| WO (1) | WO2003074082A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| CA2559228C (en) | 2004-04-21 | 2016-06-21 | Enobia Pharma Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
| US7329495B2 (en) | 2004-06-09 | 2008-02-12 | Board Of Regents, The University Of Texas System | Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors |
| KR20070045187A (ko) * | 2004-06-10 | 2007-05-02 | 고쿠리츠다이가쿠호진 도호쿠다이가쿠 | 항암제의 효과 증강제 |
| US8268785B2 (en) * | 2004-08-19 | 2012-09-18 | Switch Biotech Ag | Use of a Pde 5 inhibitor for treating and preventing hypopigmentary disorders |
| EP1759700B1 (en) * | 2004-08-19 | 2009-08-05 | Switch Biotech, LLC | Use of a PDE5 inhibitor for treating and preventing hypopigmentary disorders |
| AU2012203798B2 (en) * | 2005-08-12 | 2013-11-07 | Northrop Grumman Systems Corporation | O-nitro compounds, pharmaceutical compositons thereof and uses thereof |
| US20070135380A1 (en) | 2005-08-12 | 2007-06-14 | Radiorx, Inc. | O-nitro compounds, pharmaceutical compositions thereof and uses thereof |
| EP2237788A4 (en) * | 2007-12-27 | 2013-06-05 | Aires Pharmaceuticals Inc | COMPOUNDS FOR OBTAINING AEROSOLIZED NITRITE AND NITRIC OXIDE AND USES THEREOF |
| JP5467259B2 (ja) * | 2008-03-13 | 2014-04-09 | 国立大学法人 千葉大学 | シスプラチン効果増強剤及び抗癌剤キット |
| US20110104308A1 (en) * | 2008-05-09 | 2011-05-05 | Duke University | Treatment For Diseases Relying On Discovery That Thioredoxin Mediates Nitric Oxide |
| WO2012088608A1 (en) | 2010-12-27 | 2012-07-05 | Enobia Canada Limited Partnership | Compositions comprising natriuretic peptides and methods of use thereof |
| WO2012118042A1 (ja) * | 2011-02-28 | 2012-09-07 | 独立行政法人国立循環器病研究センター | 悪性腫瘍転移抑制用医薬 |
| JP5842367B2 (ja) * | 2011-04-07 | 2016-01-13 | ニプロ株式会社 | 抗癌剤増感剤 |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| AU2015243537B2 (en) | 2014-04-08 | 2020-10-22 | The Methodist Hospital | INOS-inhibitory compositions and their use as breast cancer therapeutics |
| WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
| MX389350B (es) | 2014-12-05 | 2025-03-19 | Alexion Pharma Inc | Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones. |
| JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
| CN108350440A (zh) | 2015-08-17 | 2018-07-31 | 阿雷克森制药公司 | 碱性磷酸酯的制造 |
| JP6868617B2 (ja) | 2015-09-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定 |
| JP2018533571A (ja) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 患者の頭蓋縫合早期癒合症を治療するための方法 |
| WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
| JP7613826B2 (ja) | 2016-04-01 | 2025-01-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼによって筋力低下を治療すること |
| US10898549B2 (en) | 2016-04-01 | 2021-01-26 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
| EP3500289B1 (en) | 2016-08-18 | 2024-10-09 | Alexion Pharmaceuticals, Inc. | Asfotase alfa for use in treating tracheobronchomalacia |
| EP3600383A4 (en) | 2017-03-31 | 2020-10-28 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| US12268733B2 (en) | 2018-08-10 | 2025-04-08 | Alexion Pharmaceuticals, Inc. | Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase |
| CA3161266A1 (en) | 2019-12-09 | 2021-06-17 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| AU2021337652B2 (en) | 2020-09-04 | 2025-01-30 | Alexion Pharmaceuticals, Inc. | Methods for treating bone mineralization disorders |
| BR112023016048A2 (pt) | 2021-02-12 | 2023-11-14 | Alexion Pharma Inc | Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos |
| CN114869894A (zh) * | 2022-05-10 | 2022-08-09 | 福州大学 | 一种小分子化合物在制备作为尿激酶受体抑制剂药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LV11542B (en) * | 1995-03-30 | 1997-02-20 | Latvijas Organiskas Sintezes Instituts | Substituted 1,3,9,11-tetraoxa-4,5,7,8-tetraazaundecadien-4,7-dioxides-5,7, preparation and use thereof |
| WO1999003462A1 (en) * | 1997-07-14 | 1999-01-28 | Brigham And Women's Hospital | Modification of nitric oxide activity to treat fas-induced pathologies |
| WO2001054680A2 (en) * | 2000-01-26 | 2001-08-02 | Cedars-Sinai Medical Center | Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor |
| US20010038832A1 (en) * | 2000-04-11 | 2001-11-08 | Benjamin Bonavida | Nitric oxide and analogues thereof effectuate sensitization of neoplasm and immunologically undesired tissues to cytotoxicity |
| ES2232613T3 (es) * | 2000-04-26 | 2005-06-01 | Cellegy Pharmaceuticals, Inc | Formulaciones y metodos de utilizacion de agentes mimeticos del oxido nitrico contra un fenotipo celular maligno. |
-
2003
- 2003-03-06 JP JP2003572598A patent/JP2005527510A/ja active Pending
- 2003-03-06 EP EP03706181A patent/EP1492567A1/en not_active Withdrawn
- 2003-03-06 WO PCT/CA2003/000313 patent/WO2003074082A1/en not_active Ceased
- 2003-03-06 AU AU2003208228A patent/AU2003208228A1/en not_active Abandoned
- 2003-03-06 CA CA002478145A patent/CA2478145A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005527510A5 (https=) | ||
| US6649645B1 (en) | Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia | |
| US8202242B2 (en) | Method of using vasoconstrictive agents during energy-based tissue therapy | |
| KR101292508B1 (ko) | 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과 조합된 ｃ-ｓｒｃ 억제제의 용도 | |
| KR20060097000A (ko) | 화학요법제와 ｖｅｇｆ 수용체 저해제의 배합물 | |
| JP2009511450A (ja) | ニロチニブとファルネシルトランスフェラーゼ阻害剤の組合せ | |
| JP2013107893A (ja) | 神経線維腫症の処置のためのピリミジルアミノベンズアミド誘導体 | |
| CA2606716C (en) | Use of pyrimidylaminobenzamide derivatives for the treatment of systematic mastocytosis | |
| JP2009520787A (ja) | Ａｚｄ２１７１およびペメトレキセドの組み合わせ | |
| JP4429732B2 (ja) | 癌の処置におけるグリベック（ｓｔｉ５７１）とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤 | |
| US12042499B2 (en) | Administration of aurora kinase inhibitor and chemotherapeutic agents | |
| US7767686B2 (en) | Method of using adenosine receptor blockers during tissue ablation | |
| WO2002022127A1 (en) | Use of phosphodiesterase inhibitors for the treatment of anorectal disorders | |
| JP5751568B2 (ja) | 悪性末梢神経鞘腫瘍の処置 | |
| WO2022167999A1 (en) | Combination therapy for cancer treatment | |
| AU2011202950B2 (en) | Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia | |
| AU2004201161B2 (en) | Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia | |
| Saiko et al. | Heterodinucleoside phosphates of 5-fluorodeoxyuridine and arabinofuranosylcytosine-New drugs in cancer chemotherapy? | |
| JPH06107548A (ja) | 癌の肝転移抑制剤及び肝癌の治療剤 | |
| JP2013525296A (ja) | 内分泌療法抵抗性乳癌の処置 | |
| JPS6115843A (ja) | 癌転移抑制剤 | |
| AU2013201915A1 (en) | Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia |